Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Bio-Matrix Scientific Group's new opportunities in cancer treatment and intellectual property discussed

Bio-Matrix Scientific Group, Inc. Chairman & CEO David Koos commented on the Company’s new opportunities in stem cell research, cancer treatment and intellectual property.

1 Sep 2009

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Peregrine Pharmaceuticals, Inc., today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program.

31 Aug 2009

Inhibitor Education Summits to address pertinent topics regarding hemophilia

More than 160 families of patients living with a rare form of hemophilia are coming together at educational summits sponsored this fall by the National Hemophilia Foundation (NHF) and the Center for Biomedical Continuing Education (CBCE). For the fifth year, the Inhibitor Education Summits will connect patients and their families with expert healthcare professionals and fellow patients to address pertinent topics such as effective pain management, exercise and nutrition, financial security, and psychological wellbeing.

29 Aug 2009

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

Haber, Inc. (“Haber”), (OTC: HABE), a Delaware corporation headquartered in Arlington, Mass., with proprietary technologies in the separations sciences and environmentally friendly processing of gold bearing ores, announced today that it has formed a wholly owned subsidiary incorporated in Delaware called “EMP Diagnostics Inc.” (“EDI”). The business of the new company will focus on the application of Haber’s Electromolecular Propulsion technology (EMP). EMP is a separation technology that achieves unrivaled molecular separation speeds and has other unique capabilities not attainable with electrophoresis or liquid chromatography.

27 Aug 2009

BMSN and ENTB collaborate with Therinjectto to develop a new immuno-therapeutic cancer vaccine

Bio-Matrix Scientific Group, Inc. and Its majority owned subsidiary Entest BioMedical Inc. announced today they have finalized a definitive agreement with Therinject LLC for the development of a new immuno-therapeutic cancer vaccine. Therinject LLC is engaged in the development of cancer treatments utilizing immunology based approaches.

27 Aug 2009

New technique for diabetes treatment may be in the offing

An exploration of the molecular links between insulin resistance and inflammation may have revealed a novel target for diabetes treatment, say scientists at the John G. Rangos Sr. Research Center, Children's Hospital of Pittsburgh of UPMC. Their findings were published earlier this month in the online version of Diabetes, one of the journals of the American Diabetes Association.

27 Aug 2009

Symptomless blood disorder MGUS not a precursor of serious diseases

A symptomless blood disorder, monoclonal gammopathy of undetermined significance, known as MGUS, is not linked to as many serious diseases as previously thought. This finding may save patients from undergoing unnecessary workup and treatment according to a study published in the August 2009 issue of Mayo Clinic Proceedings.

26 Aug 2009

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.

19 Aug 2009

Massage therapy eases sickle cell disease pain in children

Massage offers both physical and psychological benefits and is used at Nationwide Children’s Hospital in many areas including Rehabilitation, Physical Medicine and in patients who have received organ transplants, just to name a few. Researchers at Nationwide Children’s recently published a study in the Journal of Pediatric Psychology that revealed the benefits of massage in reducing pain, anxiety and depression in children with Sickle Cell Disease.

12 Aug 2009

Association of Specialty Professors announces the 2009 T. Franklin Williams scholars

The Association of Specialty Professors (ASP) is pleased to announce the eighth class of T. Franklin Williams Scholars. These scholars are recipients of two- to four-year career development awards funded by a generous grant from the Atlantic Philanthropies (USA) Inc. and the John A. Hartford Foundation, and co-sponsored by 12 internal medicine specialty societies.

10 Aug 2009

Genzyme’s Mozobil approved in Europe

Genzyme Corporation announced today that the European Commission has granted marketing authorization for Mozobil ® (plerixafor injection), providing a significant new option for patients with the blood cancers lymphoma and multiple myeloma who require an autologous stem cell transplant.

6 Aug 2009

Gene variants associated with survival advantage in African Americans with HIV

From the start of the HIV epidemic, it appeared that some of the people who were infected with the virus were able to ward off the fatal effects of the disease longer than others.

20 Jul 2009

IU Simon Cancer Center researcher heads cancer study during Indiana Black Expo's health fair

A small drop of blood can provide researchers with countless clues into cancer. You can help researchers at the Indiana University Melvin and Bren Simon Cancer Center by donating a blood sample during the Indiana Black Expo's INShape Indiana Black & Minority Health Fair.

6 Jul 2009

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN), has announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ proprietary technology to empower antibodies by linking them to potent cell-killing drugs.

18 Jun 2009

Certain pesticides double the risk of blood disorder

A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one's risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general population.

13 Jun 2009

Cremophor-based paclitaxel ‘chemo’ drug triggers fatal allergic reactions

A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.

9 Jun 2009

Protein abundant in embryonic stem cells offers a new cancer target

A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston.

1 Jun 2009

Study shows that induction chemotherapy prior to chemoradiotherapy significantly increases time-to-treatment failure in comparison to standard chemoradiotherapy alone

The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC) delivered prior to standard ChemoRadiotherapy (CRT), a treatment paradigm defined as sequential therapy, compared to upfront CRT alone, significantly prolonged Time-to-Treatment Failure (TTF) for patients with unresectable Locally Advanced Head and Neck Cancer (LAHNC).

1 Jun 2009

Bayer announces new data on novel anti-cancer compound

Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

1 Jun 2009

ChemGenex’s Omacetaxine to be showcased in three oral oresentations at EHA

ChemGenex Pharmaceuticals Limited announced today that new data from two clinical studies and one pre-clinical study with omacetaxine will be presented at oral sessions during the forthcoming 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.

21 May 2009

Hematology News and Research

Further Reading

Bio-Matrix Scientific Group's new opportunities in cancer treatment and intellectual property discussed

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Inhibitor Education Summits to address pertinent topics regarding hemophilia

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

BMSN and ENTB collaborate with Therinjectto to develop a new immuno-therapeutic cancer vaccine

New technique for diabetes treatment may be in the offing

Symptomless blood disorder MGUS not a precursor of serious diseases

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Massage therapy eases sickle cell disease pain in children

Association of Specialty Professors announces the 2009 T. Franklin Williams scholars

Genzyme’s Mozobil approved in Europe

Gene variants associated with survival advantage in African Americans with HIV

IU Simon Cancer Center researcher heads cancer study during Indiana Black Expo's health fair

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Certain pesticides double the risk of blood disorder

Cremophor-based paclitaxel ‘chemo’ drug triggers fatal allergic reactions

Protein abundant in embryonic stem cells offers a new cancer target

Study shows that induction chemotherapy prior to chemoradiotherapy significantly increases time-to-treatment failure in comparison to standard chemoradiotherapy alone

Bayer announces new data on novel anti-cancer compound

ChemGenex’s Omacetaxine to be showcased in three oral oresentations at EHA

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News